noscript

News and Announcements

PromarkerD Shows Improved Predictive Ability & Robustness

  • Published December 15, 2016 3:19PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Proteomics International Laboratories Ltd (ASX: PIQ) is pleased to provide an update on its clinical studies for PromarkerD, the company’s breakthrough test for the prediction of diabetic kidney disease.

Highlights:

  • PromarkerD predicts diabetic kidney disease across all major clinical definitions of rapid decline in kidney function
  • Predictive ability improved – PromarkerD correctly predicted 61-97% of individuals who went on to have a clinically significant decline in kidney function within four years
  • Inter-laboratory study shows robustness of PromarkerD as a future Laboratory Developed Test

There are currently 415 million adults worldwide with diabetes, and approximately one third of these people have chronic kidney disease which can lead to dialysis or kidney transplant.

To read the full announcements please click on the button below.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now